Table 2.

Key Studies in the literature on fecal microbiota transplantation in pancreatic pathology.

Authors	Study Objective	Methodology	Main Findings
Yang et al. [72]	Examined the efficacy of fecal microbiota transplantation (FMT) in treating moderately severe acute pancreatitis complicated by severe Clostridioides difficile infection (CDI).	A case study of FMT application in patient with moderately severe acute pancreatitis and severe CDI.	FMT led to the resolution of diarrhea within five days with no adverse events reported.
He et al. [81]	Investigated the efficacy of the FMT in adolescent patients with type 1 diabetes (T1D).	The administration of one to three cycles of the FMT to adolescent T1D patients with the monitoring of clinical outcomes and adjustments in therapeutic regimen.	FMT protocols showed potential as a viable treatment for autoimmune T1D, with implications for improving patient quality of life.
Li Liu et al. [91]	Explored the impact of the gut microbiota and their metabolites on acute pancreatitis (AP).	The investigation of gut dysbiosis correction through normobiotic FMT in AP patients.	Normobiotic FMT corrected gut dysbiosis caused by AP, reducing its severity including mitochondrial dysfunction, oxidative stress, and inflammation.
Ding et al. [92]	Assessed the role of the FMT in managing acute pancreatitis.	Randomized controlled trial comparing FMT versus saline administration in AP patients.	No significant difference in gastrointestinal recovery observed between FMT and saline groups. Increased levels of D-lactate and IL-6 were noted with FMT, suggesting potential adverse effects on the gastrointestinal barrier.
De Groot et al. [96]	Explored the effect of the FMT on preserving endogenous insulin production in patients with recently diagnosed T1D.	The division of participants with recent T1D onset into groups receiving autologous or allogeneic FMTs.	A significant preservation of beta-cell function observed in the autologous FMT group over 12 months, linked to specific plasma metabolites.